Geron: Rytelo’s Market Share Concerns Justified As 3L Dominates Early SalesBy mariocazombo76@gmail.com / February 26, 2025
Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris’ Path January 30, 2025 / DNA, Stephen Ayers / By mariocazombo76@gmail.com
Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain January 31, 2025 / Albert Anthony, BMY / By mariocazombo76@gmail.com